Opiant Pharmaceuticals (OPNT) Downgraded by ValuEngine to Hold
Opiant Pharmaceuticals (NASDAQ:OPNT) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
Separately, TheStreet raised shares of Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Monday, October 16th.
Opiant Pharmaceuticals (NASDAQ:OPNT) traded down $1.18 during trading on Friday, hitting $30.56. 33,583 shares of the stock were exchanged, compared to its average volume of 27,314. The stock has a market capitalization of $64.68, a price-to-earnings ratio of 10.98 and a beta of -2.19. Opiant Pharmaceuticals has a one year low of $5.00 and a one year high of $51.90.
TRADEMARK VIOLATION WARNING: “Opiant Pharmaceuticals (OPNT) Downgraded by ValuEngine to Hold” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/02/opiant-pharmaceuticals-opnt-downgraded-by-valuengine-to-hold.html.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.